It is difficult to find a field of patent law in pharma and biotech at the moment that is more complicated and fast-moving than the field of lipid nanoparticles (LNPs). IP strategy for LNPs involves sophisticated science, multiple and overlapping technology platforms, trade secret and ownership disputes and global patent cross-litigation. As we move away from historical disputes surrounding the
